![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: APRT |
Gene summary for APRT |
![]() |
Gene information | Species | Human | Gene symbol | APRT | Gene ID | 353 |
Gene name | adenine phosphoribosyltransferase | |
Gene Alias | AMP | |
Cytomap | 16q24.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P07741 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
353 | APRT | cirrhotic2 | Human | Liver | Cirrhotic | 3.19e-36 | 3.92e-01 | 0.0201 |
353 | APRT | cirrhotic3 | Human | Liver | Cirrhotic | 1.65e-27 | 3.94e-01 | 0.0215 |
353 | APRT | p6 | Human | Liver | Cyst | 2.87e-02 | -5.52e-01 | -0.0218 |
353 | APRT | HCC1 | Human | Liver | HCC | 5.32e-15 | 5.68e+00 | 0.5336 |
353 | APRT | HCC2 | Human | Liver | HCC | 1.77e-21 | 4.91e+00 | 0.5341 |
353 | APRT | Pt13.a | Human | Liver | HCC | 1.77e-09 | 2.45e-01 | 0.021 |
353 | APRT | Pt13.b | Human | Liver | HCC | 4.94e-42 | 3.43e-01 | 0.0251 |
353 | APRT | Pt14.a | Human | Liver | HCC | 4.78e-06 | 2.20e-01 | 0.0169 |
353 | APRT | Pt14.b | Human | Liver | HCC | 3.93e-11 | 3.58e-01 | 0.018 |
353 | APRT | S014 | Human | Liver | HCC | 1.68e-36 | 2.27e+00 | 0.2254 |
353 | APRT | S015 | Human | Liver | HCC | 2.10e-34 | 2.57e+00 | 0.2375 |
353 | APRT | S016 | Human | Liver | HCC | 1.60e-34 | 1.99e+00 | 0.2243 |
353 | APRT | S027 | Human | Liver | HCC | 3.04e-24 | 3.06e+00 | 0.2446 |
353 | APRT | S028 | Human | Liver | HCC | 1.32e-35 | 3.26e+00 | 0.2503 |
353 | APRT | S029 | Human | Liver | HCC | 1.93e-37 | 3.74e+00 | 0.2581 |
353 | APRT | C04 | Human | Oral cavity | OSCC | 3.65e-43 | 3.25e+00 | 0.2633 |
353 | APRT | C21 | Human | Oral cavity | OSCC | 1.76e-70 | 3.65e+00 | 0.2678 |
353 | APRT | C30 | Human | Oral cavity | OSCC | 4.63e-61 | 3.96e+00 | 0.3055 |
353 | APRT | C38 | Human | Oral cavity | OSCC | 3.20e-15 | 2.06e+00 | 0.172 |
353 | APRT | C43 | Human | Oral cavity | OSCC | 9.52e-70 | 1.58e+00 | 0.1704 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00196938 | Breast | Precancer | ribose phosphate metabolic process | 49/1080 | 396/18723 | 3.81e-07 | 1.78e-05 | 49 |
GO:00091528 | Breast | Precancer | purine ribonucleotide biosynthetic process | 28/1080 | 169/18723 | 4.17e-07 | 1.89e-05 | 28 |
GO:00463907 | Breast | Precancer | ribose phosphate biosynthetic process | 30/1080 | 190/18723 | 4.75e-07 | 2.11e-05 | 30 |
GO:00092607 | Breast | Precancer | ribonucleotide biosynthetic process | 29/1080 | 182/18723 | 6.05e-07 | 2.55e-05 | 29 |
GO:00091509 | Breast | Precancer | purine ribonucleotide metabolic process | 46/1080 | 368/18723 | 6.47e-07 | 2.71e-05 | 46 |
GO:00091179 | Breast | Precancer | nucleotide metabolic process | 56/1080 | 489/18723 | 7.40e-07 | 3.00e-05 | 56 |
GO:00092598 | Breast | Precancer | ribonucleotide metabolic process | 47/1080 | 385/18723 | 9.69e-07 | 3.84e-05 | 47 |
GO:00067539 | Breast | Precancer | nucleoside phosphate metabolic process | 56/1080 | 497/18723 | 1.24e-06 | 4.70e-05 | 56 |
GO:00061639 | Breast | Precancer | purine nucleotide metabolic process | 47/1080 | 396/18723 | 2.14e-06 | 7.50e-05 | 47 |
GO:00061647 | Breast | Precancer | purine nucleotide biosynthetic process | 28/1080 | 191/18723 | 5.04e-06 | 1.52e-04 | 28 |
GO:00487329 | Breast | Precancer | gland development | 49/1080 | 436/18723 | 6.11e-06 | 1.73e-04 | 49 |
GO:00725219 | Breast | Precancer | purine-containing compound metabolic process | 47/1080 | 416/18723 | 8.19e-06 | 2.20e-04 | 47 |
GO:00725227 | Breast | Precancer | purine-containing compound biosynthetic process | 28/1080 | 200/18723 | 1.23e-05 | 3.17e-04 | 28 |
GO:00091655 | Breast | Precancer | nucleotide biosynthetic process | 32/1080 | 254/18723 | 2.72e-05 | 6.21e-04 | 32 |
GO:19012935 | Breast | Precancer | nucleoside phosphate biosynthetic process | 32/1080 | 256/18723 | 3.18e-05 | 6.97e-04 | 32 |
GO:00508789 | Breast | Precancer | regulation of body fluid levels | 40/1080 | 379/18723 | 1.68e-04 | 2.77e-03 | 40 |
GO:00308796 | Breast | Precancer | mammary gland development | 16/1080 | 137/18723 | 5.59e-03 | 4.07e-02 | 16 |
GO:000915214 | Breast | IDC | purine ribonucleotide biosynthetic process | 34/1434 | 169/18723 | 1.63e-07 | 8.92e-06 | 34 |
GO:004639013 | Breast | IDC | ribose phosphate biosynthetic process | 36/1434 | 190/18723 | 3.40e-07 | 1.73e-05 | 36 |
GO:000926013 | Breast | IDC | ribonucleotide biosynthetic process | 35/1434 | 182/18723 | 3.40e-07 | 1.73e-05 | 35 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
hsa0123221 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
hsa0123231 | Oral cavity | LP | Nucleotide metabolism | 42/2418 | 85/8465 | 3.62e-05 | 2.36e-04 | 1.52e-04 | 42 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
APRT | SNV | Missense_Mutation | novel | c.277C>T | p.Pro93Ser | p.P93S | P07741 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
APRT | SNV | Missense_Mutation | c.496N>A | p.Glu166Lys | p.E166K | P07741 | protein_coding | tolerated(0.19) | benign(0.049) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
APRT | SNV | Missense_Mutation | rs752166198 | c.265N>T | p.Arg89Trp | p.R89W | P07741 | protein_coding | deleterious(0) | possibly_damaging(0.831) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
APRT | SNV | Missense_Mutation | c.524N>A | p.Ser175Tyr | p.S175Y | P07741 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | |
APRT | SNV | Missense_Mutation | novel | c.296C>T | p.Ala99Val | p.A99V | P07741 | protein_coding | tolerated(1) | benign(0.001) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
APRT | SNV | Missense_Mutation | novel | c.443N>T | p.Ala148Val | p.A148V | P07741 | protein_coding | tolerated(0.08) | probably_damaging(0.985) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APRT | SNV | Missense_Mutation | novel | c.112N>C | p.Ser38Pro | p.S38P | P07741 | protein_coding | deleterious(0.02) | possibly_damaging(0.794) | TCGA-EY-A5W2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APRT | SNV | Missense_Mutation | c.363G>C | p.Gln121His | p.Q121H | P07741 | protein_coding | deleterious(0.01) | probably_damaging(0.916) | TCGA-69-7979-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
APRT | SNV | Missense_Mutation | c.363N>C | p.Gln121His | p.Q121H | P07741 | protein_coding | deleterious(0.01) | probably_damaging(0.916) | TCGA-73-4658-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
APRT | SNV | Missense_Mutation | rs117335001 | c.260N>A | p.Arg87Gln | p.R87Q | P07741 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-68-8250-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
353 | APRT | ENZYME, DRUGGABLE GENOME | TPA | ALTEPLASE | 6933001 | |
353 | APRT | ENZYME, DRUGGABLE GENOME | HYDROGEN PEROXIDE | 10213488 |
Page: 1 |